Does CPhI Worldwide indicate a prosperous 2018 for Pharma?

CPhI Worldwide, organised by UBM, closed its twenty-eighth edition with pre-audit figures indicating a record-breaking attendance of more than 44,500 and 2598 exhibitors

It takes a lot of great people doing #CPhIWW. Here is the team behind the scenes

A post shared by CPhI (@cphievents) on

Held in Frankfurt, Germany, the heart of Europe’s biggest pharmaceutical market, the pharma event saw attendees from 169 countries — 25% of whom are CEO or board level. 

CPhI Worldwide is widely used as a barometer of pharma’s overall health, as it is the only platform that brings together global pharma.

More than 85% of attendance was international, with more than 6000 people travelling from China and India alone. In fact, 71% of all visitors have purchasing power, with an average annual budget of €3.5 million per department.

Remarkably, in just the last 3 years alone, CPhI Worldwide has grown its audience base by 10,000 people, pulling in new attendees from across finished formulations and biologicals — with the latter set to see further growth with the launch of a new event, BioLive in 2018.

UBM attributes the increase in attendance to its enhanced reputation as a meeting ground for pharma businesses — the event recorded more than 56,598 company searches and 952,152 interactions though its supplier finder tools — and its commitment to introducing the latest technological advances, which made CPhI Worldwide easier to navigate.

There were more than 9000 downloads of its mobile app (up 80% year-on-year) and a rise in social media engagement.

The 2017 event, also saw the launch of the world’s first ever reputation league table of major pharma industries — the CPhI Global Pharma Index — which scores the reputes of the major pharma economies across a range of attributes.

Aptly, Germany — the host country — finished top of the rankings for pharmaceutical quality in both ‘APIs’ and ‘finished dosage drugs’.

Germany was also voted by the industry as the best country for both ‘knowledge of its pharma professionals’ and ‘transparency index’ — essentially, a rank of countries with the best regulations, business transparency and anti-corruption practices. 

In total, CPhI Worldwide featured 22 country pavilions and 19 different zones covering the entire supply chain, with bio exhibitors becoming increasingly prominent.

Finally, in the celebration of the global pharmaceutical industry, the CPhI Pharma Awards also experienced a good year, doubling the number of entries and finalists — with more than 200 submissions and 19 innovative winners.

“CPhI Worldwide continues to lead the way for pharma globally and the event is fundamental to how our global industry meets new partners, learns about the latest trends and does the deals driving forward drug development and commercial production.”

“With a record breaking event and nearly 44,500 attendees, 2018 looks set to be another stellar year for pharma. But it is also going to be a huge year for UBM, as we expand our reach into the MENA region — with CPhI MEA — and introduce a dedicated bio processing event, BioLive, to run parallel to CPhI next year in Madrid,” said Orhan Caglayan, Brand Director Europe, UBM EMEA.

 

Companies